This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Search for Biomarkers in Human Glaucoma: Lymphocytes Alterations and Rate of Progression

This study has been completed.
Information provided by:
University of Parma Identifier:
First received: September 21, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
The aim of this study was to evaluate the lymphocyte phenotype in primary open- angle glaucoma (POAG) patients compared to healthy subjects of the same age, in order to confirm the importance of immune responses in glaucoma and the possible correlation to the severity of the disease.

Glaucoma, Open-Angle

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Search for Biomarkers in Human Glaucoma: Possible Correlations Between Alterations in Peripheral Lymphocytes and Disease Severity

Resource links provided by NLM:

Further study details as provided by University of Parma:

Primary Outcome Measures:
  • compare the lymphocyte phenotype of POAG patients to healthy subjects of the same age [ Time Frame: the same day of bloodwithdrawal ]

Secondary Outcome Measures:
  • correlate the immunophenotype of POAG patients to the severity of disease [ Time Frame: within 3 months after blood withdrawal ]

Enrollment: 40
Study Start Date: June 2007
Study Completion Date: June 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Glaucoma patients
POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation


Ages Eligible for Study:   19 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic in Parma (University hospital of Parma)

Inclusion Criteria:

  • Clinical diagnosis of primary open-angle glaucoma
  • age between 19 an 85 years old

Exclusion Criteria:

  • age less than 19 or more than 85 yrs
  • positive history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection and (e) diabetes, (f)systemic inflammation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00981422

Azienda ospedaliera universitaria
Parma, Italy, 43100
Sponsors and Collaborators
University of Parma
Principal Investigator: Stefano A Gandolfi, MD Ophthalmology Institute, University of Parma, Italy
  More Information

Responsible Party: STEFANO GANDOLFI, Professor of Ophthalmology and Chairman, UNIVERSITY OF PARMA Identifier: NCT00981422     History of Changes
Other Study ID Numbers: PARMABIOMARKERS001
Study First Received: September 21, 2009
Last Updated: September 21, 2009

Keywords provided by University of Parma:

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases processed this record on August 23, 2017